Skip to main content
main-content

Type 2 diabetes

Highlights

10-01-2019 | Older adults | Highlight | News

Type 2 diabetes sex disparities persist into very old age

Known sex differences among younger patients with type 2 diabetes persist among those aged 90 years and older, particularly optimal use of cardiovascular preventive therapies which is significantly less likely among women than men, Spanish research shows.

09-20-2019 | Insulin degludec | EASD 2019 | News

Long-acting insulins result in similar overall hypoglycemia rates, CONCLUDEs study

The CONCLUDE trial has demonstrated similar overall rates of symptomatic hypoglycemia among type 2 diabetes patients treated with insulin degludec U200 or insulin glargine U300.

09-20-2019 | Nephropathy | EASD 2019 | News

Mixed results for PRIORITY diabetic nephropathy trial

The CKD273 proteomic biomarker panel can predict which people with type 2 diabetes will develop detectable diabetic nephropathy, but early intervention with spironolactone does not mitigate this risk, report the PRIORITY investigators.

09-20-2019 | Heart failure | Video | Article

Researcher comment: The DEFINE-HF trial results

Mikhail Kosiborod outlines the findings from the DEFINE-HF trial, and discusses the possible reasons why dapagliflozin had an impact on one primary endpoint but not the other (5:48).

09-20-2019 | Nephropathy | Video | Article

Expert commentary: The PRIORITY trial results

Luigi Gnudi discusses the findings of the PRIORITY trial and addresses whether diabetologists should consider intervening earlier in diabetic nephropathy (4:08).

09-20-2019 | Insulin degludec | Video | Article

Researcher comment: The CONCLUDE trial

Athena Philis-Tsimikas discusses which patients may benefit the most from treatment with long-acting insulins, and how the data from CONCLUDE compare with real-world study findings (2:38).

09-19-2019 | Medications | Video | Article

Expert commentary: Trial results of imeglimin in type 2 diabetes

John Wilding comments on study results highlighting that imeglimin, an agent targeting mitochondrial bioenergetics, may represent a novel therapeutic approach for type 2 diabetes (2:17).

09-19-2019 | Vildagliptin | Highlight | Article

Expert commentary: The VERIFY trial results

Amrit Lamba discusses how the findings of VERIFY may influence how primary care practitioners will approach first-line treatment of people with type 2 diabetes (4:32).

09-19-2019 | Heart failure | Video | Article

Expert commentary: DAPA-HF and DEFINE-HF trial results

Lars Rydén discusses how the results of the DAPA-HF and DEFINE-HF trials will impact treatment decisions for patients with heart failure (6:38).

09-19-2019 | Medications | EASD 2019 | News

Imeglimin shows promise for type 2 diabetes

Imeglimin, an agent that improves mitochondrial function, has demonstrated potential as a novel treatment option for Japanese patients with type 2 diabetes in the phase III TIMES 1 and TIMES 3 trials.

09-19-2019 | Heart failure | Video | Article

Researcher comment: The DAPA-HF trial results

John McMurray talks about the results of the DAPA-HF trial, discussing whether the benefits of dapagliflozin for patients with heart failure could be extended to other SGLT2 inhibitors, and the next steps for research (3:29).

09-18-2019 | Semaglutide | EASD 2019 | News

Semaglutide tops liraglutide in SUSTAIN 10

Findings from the SUSTAIN 10 trial show that semaglutide results in better glycemic control than liraglutide when added to oral antidiabetic drugs in people with type 2 diabetes.

09-18-2019 | Semaglutide | EASD 2019 | News

SUSTAIN 8: Semaglutide outperforms canagliflozin as second-line therapy for type 2 diabetes

Treatment with the glucagon-like peptide-1 receptor agonist semaglutide results in better glycemic control than the sodium-glucose cotransporter 2 inhibitor canagliflozin among people with type 2 diabetes uncontrolled on metformin, indicate the SUSTAIN 8 trial results.

09-18-2019 | Vildagliptin | EASD 2019 | News

Trial results VERIFY first-line combination therapy for type 2 diabetes

Upfront combination therapy with vildagliptin and metformin is more durable than metformin alone, and appears to have a legacy effect, report the VERIFY investigators.

09-18-2019 | Cardiovascular outcomes | EASD 2019 | News

Collaborative type 2 diabetes care model has lasting benefits

Ten-year results from the Beijing Community Diabetes Study indicate that collaborative care delivered by primary care providers and specialists may result in sustained improvements in cardiovascular risk factor control among people with type 2 diabetes.

09-05-2019 | Obesity | Highlight | News

Metabolic surgery may improve cardiovascular prognosis in type 2 diabetes

People with type 2 diabetes and obesity who undergo metabolic surgery have a significantly lower risk for major adverse cardiovascular events than those who do not receive surgery, observational study data show.

09-02-2019 | Heart failure | Highlight | News

Dapagliflozin ‘offers a new approach’ for treating heart failure

The addition of dapagliflozin to standard treatment may be beneficial for patients with established heart failure and reduced ejection fraction, indicate findings from the DAPA-HF trial.

08-23-2019 | Canagliflozin | Highlight | News

CANVAS canagliflozin fracture effect may be chance finding

A comparison of CANVAS and CANVAS-R fails to detect any potential explanation for the increased fracture risk seen with canagliflozin versus placebo in the former trial.

08-19-2019 | GLP-1 agonists | Highlight | News

Meta-analysis demonstrates cardioprotective effect of GLP-1 receptor agonists

Treatment with glucagon-like peptide receptor agonists reduces the risk for major adverse cardiovascular events among people with type 2 diabetes, indicate findings from a large meta-analysis.

08-12-2019 | Metabolic surgery | Highlight | News

Bariatric surgery linked to late adverse events

People who undergo bariatric surgery have a lower long-term risk for mortality, but a higher risk for adverse events such as gastrointestinal and nutritional disorders, compared with those who do not undergo surgery, researchers report.

Read the linked commentary from John Wilding

Image Credits